China faces a significant and growing burden from kidney diseases, driven by an aging population, rising rates of diabetes and hypertension, and the increasing complexity of critical care. In this challenging environment, Continuous Renal Replacement Therapy (CRRT) has become an indispensable tool for managing critically ill patients with acute kidney injury (AKI) and other life-threatening conditions. The China Continuous Renal Replacement Therapy Market is experiencing robust growth, reflecting the nation's commitment to advancing its critical care infrastructure. Valued at USD 246 million in 2024, the market is projected to reach USD 487 million by 2035, growing at a steady CAGR of 6.41% . This expansion is fueled by the increasing prevalence of chronic kidney diseases, supportive government policies, and rapid technological innovations in dialysis equipment.

The Critical Role of CRRT in Modern Medicine

The China Continuous Renal Replacement Therapy Market provides a lifeline for the most vulnerable patients. CRRT is a form of dialysis that is slower and gentler than traditional intermittent hemodialysis, making it ideal for patients with hemodynamic instability, often found in intensive care units . It is primarily used to treat Acute Kidney Injury (AKI), which is the largest application segment, but its use is expanding to manage Chronic Kidney Disease (CKD), the fastest-growing application, and multiple organ failure . The market's growth is being driven by the rising number of critically ill patients requiring this therapy. In 2025, global estimates suggest that over 50% of acute patients (around 1.1 million) received CRRT, a number expected to grow to 1.5 million by 2035 .

Key Drivers: Policy, Aging Population, and Technology

Several powerful factors are fueling the growth of the China Continuous Renal Replacement Therapy Market. A primary driver is the strong government support for improving healthcare infrastructure, particularly in critical care. Policies such as the Improving Critical Care Medical Service Capacity Plan and the Medical Infrastructure Strengthening Project are mandating the expansion of ICU beds and the acquisition of life-saving equipment like CRRT devices, especially in county-level hospitals . The demographic shift towards an aging population is another critical driver. As the number of elderly individuals increases, the prevalence of age-related health issues, including chronic kidney diseases, rises, creating sustained demand for renal therapies . Technological innovation is also a key driver, with the development of portable dialysis machines, AI-driven platforms for personalized treatment, and automated systems enhancing treatment efficacy and patient outcomes .

Market Segmentation and Competitive Landscape

The China CRRT market is segmented by product type, end-user, techniques, and application. By product type, Continuous Veno-Venous Hemofiltration (CVVH) is the largest revenue-generating segment, but Continuous Veno-Venous Dialysis (CVVHD) is the fastest-growing, reflecting a shift in clinical preferences . By end-user, Hospitals remain the dominant segment, but Home Care Settings are emerging as the fastest-growing, driven by a patient preference for at-home treatments and the development of portable devices . The competitive landscape is dynamic, historically dominated by multinationals like Fresenius Medical Care and Baxter International . However, domestic players, led by Shanwaishan, are rapidly gaining ground. In 2025, Shanwaishan achieved an 18.32% market share in the CRRT device segment, ranking first and successfully displacing some foreign competitors .

Future Outlook and Strategic Opportunities

The future of the China Continuous Renal Replacement Therapy Market is promising, with substantial opportunities for innovation. The development of portable CRRT devices for home use is a key growth area, aligning with the trend towards patient-centered care . The integration of AI for patient monitoring and data analysis is another major opportunity, enabling personalized treatment protocols . As China continues to invest in its healthcare infrastructure and domestic manufacturers gain technological parity, the market is poised for significant expansion and innovation by 2035.